tiprankstipranks
Advertisement
Advertisement
Lanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints
PremiumRatingsLanifibranor’s Emerging Role in the MASH Market: Physician Sentiment and Uptake Potential Support a Buy Rating Despite Cash Constraints
1M ago
Inventiva initiated with a Buy at Truist
Premium
The Fly
Inventiva initiated with a Buy at Truist
2M ago
Inventiva: Strong Balance Sheet and Late-Stage MASH Candidate Lanifibranor Drive Compelling Buy Rating
Premium
Ratings
Inventiva: Strong Balance Sheet and Late-Stage MASH Candidate Lanifibranor Drive Compelling Buy Rating
3M ago
Positive Buy Rating for Inventiva Driven by Promising Phase 3 Trial and Strong Financial Position
PremiumRatingsPositive Buy Rating for Inventiva Driven by Promising Phase 3 Trial and Strong Financial Position
5M ago
Inventiva price target lowered to $11 from $13 at Guggenheim
Premium
The Fly
Inventiva price target lowered to $11 from $13 at Guggenheim
6M ago
Inventiva 32.47M share Spot Secondary priced at $3.85
Premium
The Fly
Inventiva 32.47M share Spot Secondary priced at $3.85
6M ago
Inventiva S.A. trading halted, volatility trading pause
PremiumThe FlyInventiva S.A. trading halted, volatility trading pause
6M ago
Inventiva files $300M mixed securities shelf
Premium
The Fly
Inventiva files $300M mixed securities shelf
7M ago
Buy Rating for Inventiva: Lanifibranor’s Potential as a Foundational MASH Therapy
Premium
Ratings
Buy Rating for Inventiva: Lanifibranor’s Potential as a Foundational MASH Therapy
7M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100